Welcome to our dedicated page for Acadia Pharmaceuticals news (Ticker: ACAD), a resource for investors and traders seeking the latest updates and insights on Acadia Pharmaceuticals stock.
Acadia Pharmaceuticals Inc (ACAD) delivers innovative therapies for central nervous system disorders and rare diseases through targeted research and clinical development. This dedicated news hub provides investors and healthcare professionals with essential updates on ACAD's progress in neurology and neuro-rare disease treatments.
Access timely reports on clinical trial milestones, regulatory developments, and strategic partnerships. Our curated collection includes updates on Parkinson's Disease Psychosis therapies, Rett syndrome research advancements, and pipeline progress across ACAD's neuroscience portfolio. Each release maintains scientific rigor while remaining accessible to both medical experts and investment analysts.
Key coverage areas include FDA submissions, peer-reviewed study publications, and collaborative research initiatives. Bookmark this page for centralized access to ACAD's latest scientific achievements and operational updates, carefully vetted for accuracy and relevance to long-term therapeutic development.
Acadia Pharmaceuticals (NASDAQ: ACAD) announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference, scheduled for June 9, 2025, at 4:00 p.m. Eastern Time. The company will engage in a fireside chat that will be webcast live on Acadia.com's investor section, with the recording available for approximately one month afterward.
Acadia is a neuroscience-focused pharmaceutical company known for developing the first FDA-approved treatment for Parkinson's disease psychosis-related hallucinations and delusions, as well as the first approved drug for Rett syndrome in the US and Canada. The company's current clinical-stage pipeline includes programs targeting Prader-Willi syndrome, Alzheimer's disease psychosis, and various other neuroscience and neuro-rare diseases.
Acadia Pharmaceuticals (NASDAQ: ACAD) has appointed Allyson McMillan-Youngblood as Senior Vice President of their Rare Disease Franchise. In her new role, she will focus on maximizing the potential of DAYBUE® and preparing for future product launches in the company's rare disease portfolio. McMillan-Youngblood brings over 20 years of pharmaceutical industry experience, most recently serving as Senior Vice President and Business Unit Head of U.S. Oncology at Bristol Myers Squibb, where she led two major acquisitions in rare tumors. Her extensive background includes roles at Pfizer and BMS across various therapeutic areas including oncology, immunology, CNS, and cardiovascular disorders.
Acadia Pharmaceuticals (NASDAQ: ACAD) has granted inducement awards to 28 new employees under its 2024 Inducement Plan, as approved by the Compensation Committee. The awards include 64,252 non-qualified stock options with an exercise price of $14.81 per share and 56,277 restricted stock units (RSUs).
The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over four years, with 50% vesting after two years and the remaining 50% in two equal annual installments. Both awards are subject to continued employment.
Acadia is a neuroscience company known for developing the first FDA-approved treatment for Parkinson's disease psychosis and Rett syndrome in the US and Canada. Their pipeline includes programs for Prader-Willi syndrome and Alzheimer's disease psychosis.
Acadia Pharmaceuticals (NASDAQ: ACAD) reported strong Q1 2025 financial results with total revenues of $244.3 million, up 19% year-over-year. The company's two key products showed significant growth: NUPLAZID net sales reached $159.7 million (+23% YoY) and DAYBUE achieved $84.6 million (+11% YoY). DAYBUE reached a record of 954 unique patients, and the company expanded its field force by 30%. Acadia maintained its 2025 guidance with total revenues of $1.03-$1.095 billion, while increasing R&D expense guidance to $330-$350 million due to accelerated timeline for the ACP-101 Phase 3 study in Prader Willi Syndrome, now expected in early Q4 2025.
The company reported Q1 net income of $19.0 million ($0.11 per share) compared to $16.6 million ($0.10 per share) in Q4 2024. Cash position stood at $681.6 million as of March 31, 2025.
Acadia Pharmaceuticals (NASDAQ: ACAD) announced its participation in a fireside chat at the BofA Securities 2025 Health Care Conference on May 13, 2025, at 3:40 p.m. Pacific Time. The presentation will be available via webcast on the company's website and archived for approximately one month.
Acadia is a neuroscience-focused pharmaceutical company that has developed the first FDA-approved treatment for Parkinson's disease psychosis-related hallucinations and delusions, as well as the first approved drug for Rett syndrome in the US and Canada. The company's pipeline includes clinical-stage programs targeting Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuroscience and neuro-rare diseases.
Acadia Pharmaceuticals (Nasdaq: ACAD) has scheduled its first quarter 2025 financial results announcement for May 7, 2025, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day.
The webcast will be accessible through Acadia's website investor section and archived until August 6, 2025. Interested participants can register for the conference call to receive dial-in details and a unique PIN.
Acadia specializes in neuroscience breakthroughs and has achieved notable milestones, including developing the first FDA-approved treatment for Parkinson's disease psychosis-related hallucinations and delusions, as well as the first approved treatment for Rett syndrome in the United States and Canada. Their current clinical-stage research focuses on Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuro-psychiatric and neuro-rare diseases.
Acadia Pharmaceuticals (NASDAQ: ACAD) has announced the granting of inducement awards to twenty-two new employees under its 2024 Inducement Plan. The awards, approved by the Compensation Committee on April 3, 2025, include:
- Non-qualified stock options to purchase 172,637 shares at $16.12 per share
- 64,791 restricted stock units (RSUs)
The stock options will vest over 4 years, with 25% vesting after one year and the remainder monthly over 36 months. RSUs will vest over 4 years, with 50% vesting at the second anniversary and the remaining in two equal annual installments.
Acadia specializes in neuroscience breakthroughs and has developed FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. Their clinical-stage pipeline includes programs for Prader-Willi syndrome and Alzheimer's disease psychosis.
FAQ
What is the current stock price of Acadia Pharmaceuticals (ACAD)?
What is the market cap of Acadia Pharmaceuticals (ACAD)?
